Key Points
Terumo expects $0.11 EPS and $1.84B revenue, down from recent quarters.
Historical volatility shows two beats, one miss in last four quarters, creating uncertainty.
Strong balance sheet with 11.7% net margin and 77.86x interest coverage provides stability.
Stock down 35% annually at $12.28, trading at 21.6x PE with B+ Meyka grade indicating caution.
Terumo Corporation, a leading global medical device manufacturer, reports earnings on May 15, 2026. The TRUMY stock trades at $12.28 with a market cap of $18.17 billion. Analysts expect earnings per share of $0.11 and revenue of $1.84 billion. The company faces a critical test after recent earnings showed volatility. Last quarter, Terumo beat EPS estimates but missed on revenue. Investors will focus on cardiac and vascular product demand, medical care solutions growth, and blood technology segment performance. The earnings preview reveals what to expect from this healthcare leader.
Earnings Estimates and Historical Performance
Analysts project Terumo will report $0.11 EPS and $1.84 billion in revenue for the upcoming quarter. This represents a significant decline from recent quarters, signaling potential headwinds.
Recent Quarter Comparison
The previous quarter showed $0.14 EPS actual versus $0.1453 estimate, a narrow beat. Revenue came in at $1.94 billion against a $1.86 billion estimate, exceeding expectations. Two quarters prior, Terumo delivered $0.20 EPS on a $0.1656 estimate, a strong 21% beat. However, the quarter before that showed $0.08 EPS versus $0.1454 estimate, a significant miss. This pattern reveals inconsistent execution and margin volatility.
What the Estimates Mean
The $0.11 EPS estimate sits below the recent $0.14 result, suggesting profit pressure. Revenue guidance at $1.84 billion falls slightly below the $1.94 billion prior quarter. This decline could reflect seasonal factors, currency headwinds, or slower demand in key markets. Investors should watch whether management attributes weakness to temporary factors or structural challenges in the medical device sector.
Key Segments and What to Watch
Terumo operates three major business segments that drive profitability and growth. Each segment faces distinct market dynamics and competitive pressures heading into this earnings report.
Cardiac and Vascular Company
This segment represents Terumo’s largest revenue driver, offering angiographic catheters, coronary stents, and vascular closure devices. Demand for cardiac interventions remains steady as aging populations require more procedures. However, competition from larger players like Boston Scientific and Abbott pressures pricing. Investors should monitor whether this segment maintained volume despite margin compression.
Medical Care Solutions Company
This division provides syringes, infusion pumps, blood glucose monitors, and contract manufacturing services. It generates stable recurring revenue but faces pricing pressure from healthcare cost containment. The segment’s growth depends on volume gains in emerging markets and new product adoption. Watch for commentary on prefilled syringe demand and pharmaceutical partnerships.
Blood and Cell Technologies Company
This segment offers blood bags, automated processing systems, and cell expansion technology. It benefits from growing demand for blood transfusions and cell therapies. However, regulatory changes and competition from Haemonetics and Grifols create headwinds. Management guidance on this segment’s growth trajectory matters significantly for long-term valuation.
Financial Health and Valuation Metrics
Terumo maintains a solid balance sheet with manageable debt and strong cash generation. Key metrics reveal both strengths and concerns for investors evaluating the stock.
Profitability and Margins
The company reports a net profit margin of 11.7%, indicating healthy operational efficiency. Gross margin stands at 53.3%, reflecting strong pricing power on core products. Operating margin of 16.2% shows disciplined cost management. However, recent quarters show margin compression, suggesting pricing pressure or unfavorable product mix shifts. Investors should listen for management commentary on margin sustainability.
Cash Flow and Debt Position
Operating cash flow per share reaches $143.21, while free cash flow per share stands at $91.33. The debt-to-equity ratio of 0.26 remains conservative. Interest coverage of 77.86x indicates minimal financial risk. This strong cash position supports dividends and strategic investments. The company pays a 1.5% dividend yield, attractive for income-focused investors.
Valuation Concerns
The stock trades at a PE ratio of 21.6x, above historical averages for medical device makers. Price-to-sales ratio of 2.59x suggests premium valuation. The stock has declined 35% over the past year, trading near 52-week lows of $12.08. This valuation compression reflects market concerns about growth and margin sustainability.
Beat or Miss Prediction and Meyka AI Grade
Based on historical patterns and current market conditions, Terumo faces a mixed outlook for this earnings report.
Historical Beat/Miss Pattern
Terumo shows inconsistent earnings delivery. The last four quarters reveal two beats, one miss, and one narrow beat on EPS. Revenue performance proves more reliable, with three of four quarters meeting or exceeding estimates. This pattern suggests management can control costs but struggles with revenue predictability. The current $0.11 EPS estimate sits below recent results, increasing beat probability if execution remains stable.
Prediction: Likely Miss on Revenue, Possible EPS Beat
The $1.84 billion revenue estimate appears achievable but tight. Currency headwinds and slower international demand create downside risk. EPS could beat if the company maintains cost discipline despite revenue pressure. However, margin compression from recent quarters suggests limited upside surprise potential. Investors should expect a cautious tone from management.
Meyka AI Grade: B+
Meyka AI rates TRUMY with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating reflects solid fundamentals but concerns about growth deceleration and valuation. The company scores well on profitability metrics and cash flow but faces headwinds on growth and relative valuation. These grades are not guaranteed and we are not financial advisors.
Final Thoughts
Terumo faces a critical earnings test on May 15 with $0.11 EPS and $1.84 billion revenue expected. Historical volatility and recent margin pressure create uncertainty, though the company’s strong balance sheet and cash generation provide stability. The stock’s 35% annual decline reflects market concerns about growth and valuation. Investors should focus on segment performance, margin trends, and management guidance on international demand. The B+ Meyka AI grade indicates solid fundamentals but caution warranted. Watch for commentary on pricing power, product mix, and 2026 outlook to determine if the stock offers value at current levels.
FAQs
What EPS and revenue does Terumo expect to report?
Analysts estimate $0.11 EPS and $1.84 billion revenue, down from prior quarter’s $0.14 EPS and $1.94 billion, indicating potential margin or demand pressures in medical devices.
Has Terumo beaten earnings estimates recently?
Results are mixed: last quarter beat EPS but missed revenue; two quarters prior showed 21% EPS beat; prior quarter missed EPS significantly. This inconsistency reflects execution challenges and market volatility.
What should investors watch during the earnings call?
Monitor cardiac and vascular segment demand, margin trends, and international commentary. Listen for pricing power, currency impacts, 2026 guidance, blood technology growth, and pharmaceutical partnerships affecting valuation.
What does the B+ Meyka AI grade mean for TRUMY?
B+ indicates solid fundamentals with neutral recommendation. Strong profitability and cash flow support the rating, but growth deceleration concerns and premium valuation temper enthusiasm, reflecting balanced risk-reward.
Why has TRUMY stock declined 35% over the past year?
Decline reflects growth deceleration, margin compression, premium valuation, competitive pressures in medical devices, currency headwinds, and healthcare cost containment pressuring results and investor sentiment.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)